文献检索文档翻译深度研究

邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

不再提醒

插件&应用

Zotero 插件浏览器插件 Mac 客户端 Windows 客户端微信小程序

高级版

套餐订阅购买积分包

AI 工具

文献检索文档翻译深度研究

关于我们

关于 Suppr 公司介绍联系我们用户协议隐私条款

关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究

粤ICP备2023148730 号-1Suppr @ 2025

Implications for practice: phase II/III trial of carboplatin and irinotecan for elderly patients with extensive-stage small-cell lung cancer in Japan.

作者信息

Maheshwari Shipra, Gentzler Ryan D

机构信息

Division of Hematology, Department of Medicine, University of Virginia Cancer Center, Charlottesville, VA, USA.

出版信息

J Thorac Dis. 2024 Sep 30;16(9):6342-6346. doi: 10.21037/jtd-24-279. Epub 2024 Sep 23.

DOI:10.21037/jtd-24-279

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11494565/

Abstract

摘要

相似文献

[1]

Implications for practice: phase II/III trial of carboplatin and irinotecan for elderly patients with extensive-stage small-cell lung cancer in Japan.

J Thorac Dis. 2024-9-30

[2]

Carboplatin and irinotecan (CI) vs. carboplatin and etoposide (CE) for the treatment of extended-stage small-cell lung cancer in an elderly population: A phase II/III randomized control trial.

Lung Cancer. 2023-7

[3]

A Phase II/III study comparing carboplatin and irinotecan with carboplatin and etoposide for the treatment of elderly patients with extensive-disease small-cell lung cancer (JCOG1201).

Jpn J Clin Oncol. 2015-1

[4]

A combination chemotherapy of carboplatin and irinotecan with granulocyte colony-stimulating factor (G-CSF) support in elderly patients with small cell lung cancer.

Lung Cancer. 2006-8

[5]

A randomized phase II trial of irinotecan plus carboplatin versus etoposide plus carboplatin treatment in patients with extended disease small-cell lung cancer.

Ann Oncol. 2006-4

[6]

Phase I/II study of induction chemotherapy using carboplatin plus irinotecan and sequential thoracic radiotherapy (TRT) for elderly patients with limited-disease small-cell lung cancer (LD-SCLC): TORG 0604.

BMC Cancer. 2017-5-26

[7]

Phase II study of IRInotecan treatment after COmbined chemo-immunotherapy for extensive-stage small cell lung cancer: Protocol of IRICO study.

Thorac Cancer. 2023-10

[8]

A phase II study of carboplatin and etoposide plus durvalumab for previously untreated extensive-stage small-cell lung cancer (ES-SCLC) patients with a poor performance status (PS): NEJ045A study protocol.

BMC Cancer. 2022-11-4

[9]

Should irinotecan or etoposide be used in combination with carboplatin for small cell lung cancer?

Nat Clin Pract Oncol. 2009-3

[10]

A feasibility study of carboplatin plus irinotecan treatment for elderly patients with extensive disease small-cell lung cancer.

Jpn J Clin Oncol. 2013-12-13

本文引用的文献

[1]

Carboplatin and irinotecan (CI) vs. carboplatin and etoposide (CE) for the treatment of extended-stage small-cell lung cancer in an elderly population: A phase II/III randomized control trial.

Lung Cancer. 2023-7

[2]

A Geriatric Assessment Intervention to Reduce Treatment Toxicity Among Older Adults With Advanced Lung Cancer: A Subgroup Analysis From a Cluster Randomized Controlled Trial.

Front Oncol. 2022-3-31

[3]

Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN.

ESMO Open. 2022-4

[4]

Lung Cancer in Japan.

J Thorac Oncol. 2022-3

[5]

Extensive-Stage Small-Cell Lung Cancer: First-Line and Second-Line Treatment Options.

J Clin Oncol. 2022-2-20

[6]

First-line treatment for lung cancer among Japanese older patients: A real-world analysis of hospital-based cancer registry data.

PLoS One. 2021

[7]

Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities.

Cancer Cell. 2021-3-8

[8]

Small-cell lung cancer.

Nat Rev Dis Primers. 2021-1-14

[9]

Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study.

J Clin Oncol. 2020-7-20

[10]

Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial.

Lancet. 2019-10-4

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

推荐工具

医学文档翻译智能文献检索